证券代码：832566 证券简称：梓橦宫 公告编号：2024-038 四川梓橦宫药业股份有限公司 利润分配管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 四川梓橦宫药业股份有限公司于 2024 年 4 月 2 日召开第四届董事会第三次 会议，审议通过《关于修订<利润分配管理制度>的议案》，表决结果：同意 7 票； 反对 0 票；弃权 0 票。本议案尚需提交公司股东大会审议。 二、 制度的主要内容，分章节列示： 四川梓橦宫药业股份有限公司 利润分配管理制度 第一章 总则 第一条 为进一步规范四川梓橦宫药业股份有限公司（以下简称"公司"） 的利润分配行为，建立科学、持续、稳定的分配机制，增强利润分配的透明度， 保证公司长远可持续发展，保护中小投资者合法权益，根据《中华人民共和国公 司法》（以下简称《公司法》）《中华人民共和国证券法》（以下简称《证券法》）、 《北京证券交易所股票上市规则（试行）》（以下简称《上市规则》）《上市公司监 管指引第 3 号—上市公司现金分红（2023 ...

经核查独立董事程志鹏、黄元林、马毅的任职经历以及签署的相关自查报告， 结合其他相关资料文件，董事会就独立董事的独立性形成如下结论： （一） 独立董事及其配偶、父母、子女、具有主要社会关系的人员未在公司 或公司附属企业任职； （二） 独立董事及其配偶、父母、子女未直接或间接持有公司已发行股份百 分之一以上，不是公司前十名股东中的自然人股东； （三） 独立董事及其配偶、父母、子女不是直接或间接持有公司已发行股份 百分之五以上的股东，未在公司前五名股东任职； （四） 独立董事及其配偶、父母、子女未在公司控股股东、实际控制人的附 属企业任职； 证券代码：832566 证券简称：梓橦宫 公告编号：2024-031 四川梓橦宫药业股份有限公司 董事会关于独立董事独立性自查情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 根据《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等法律法规相关 规定，四川梓橦宫药业股份有限公司（以 ...

一、 基本情况 公司第三届董事会财务与审计委员会由 3 名董事组成，分别为黄元林、程志 鹏、李云，其中黄元林、程志鹏为独立董事，主任委员（召集人）由会计专业人 士黄元林担任。 根据《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关规定，公 司于 2023 年 12 月 28 日召开 2023 年第六次临时股东大会完成第四届董事会换 届选举。第四届董事会由 7 名董事组成，其中独立董事 3 名。公司于 2024 年 1 月 2 日召开第四届董事会第一次会议，第四届董事会财务与审计委员会由 3 名董 事组成，分别为黄元林、马毅、唐铣，其中黄元林、马毅为独立董事，主任委员 （召集人）由会计专业人士黄元林担任。 二、 会议召开情况 证券代码：832566 证券简称：梓橦宫 公告编号：2024-032 四川梓橦宫药业股份有限公司 2023 年度董事会财务与审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 四川 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等有关规定和要求，四 川梓橦宫药业股份有限公司（以下简称"公司"）董事会财务与审计委员会本着 勤勉尽责的原则，恪尽职守，认真履职，对中汇会计师事务所（特殊普通合伙） （以下简称"中汇会所"）2023 年度审计工作履行了监督职责，现将情况汇报如 下： 一、 会计师事务所基本情况 （一）会计师事务所基本情况 中汇会计师事务所（特殊普通合伙）成立于 2013 年 12 月 19 日，注册地址 为杭州市江干区新业路 8 号华联时代大厦 A 幢 601 室。截至 2023 年 12 月 31 日， 合伙人数量为 103 位，注册会计师人数为 701 人，签署过证券服务业务审计报告 的注册会计师人数为 282 人。2022 年度上市公司（含 A、B 股）审计客户 159 家， 收入总额 1.37 亿元。涉及主要行业有制造业，信息传输、软件和信息技术服 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-040 （二）变更前后会计政策的介绍 1.变更前采取的会计政策： 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 2.变更后采取的会计政策： 本次会计政策变更后，公司将按照财政部发布的准则解释第 16 号要求执行。 其他未变更部分，仍按照原会计政策相关规定执行。 （三）变更原因及合理性 财政部于 2022 年 11 月 30 日发布了《企业会计准则解释第 16 号》，其中"关 于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处 理"的相关内容自 2023 年 1 月 1 日起施行。 四川梓橦宫药业股份有限公司 会计政策变更公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、变更概述 （一）变更日期：2023 年 1 月 1 日 五、本次会计政策变更对公司的影响 （一）无法追溯调整的/不采用追溯调整的 本次会计政策变 ...

四川梓橦宫药业股份有限公司 2023 年度独立董事述职报告 证券代码：832566 证券简称：梓橦宫 公告编号：2024-029 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 2023 年度，公司共召开了 8 次董事会，7 次股东大会，本人通过现场或网络 方式按时出席会议，没有委托他人出席会议或缺席的情形。认真履行相关审批程 序，独立、客观、审慎地发表意见并行使表决权，对审议的议案均无异议，也无 弃权、反对情形。出席会议情况如下： | | 董事会 | | | 股东大会 | | | | --- | --- | --- | --- | --- | --- | --- | | 应出席 次数 | 实际出 席次数 | 出席会议 方式 | 投票情况 | 应出席 次数 | 实际出 席次数 | 出席会议方式 | | 8 | 8 | 网络方式 | 同意 | 7 | 7 | 现场+网络方 式 | 二、参与董事会专门委员会、独立董事专门会议工作的情况 (一) 参与董事会专门委员会会议情况 公司董事会下设四个专门委员会，本人 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥408.05 million, a decrease of 7.71% compared to ¥442.16 million in 2022[27]. - The net profit attributable to shareholders for 2023 was approximately ¥102.32 million, showing a slight increase of 0.25% from ¥102.07 million in 2022[27]. - The net profit after deducting non-recurring gains and losses was approximately ¥88.28 million, representing a growth of 12.09% compared to ¥78.76 million in 2022[27]. - The gross profit margin for 2023 was 80.94%, an increase from 79.96% in 2022[27]. - The basic earnings per share for 2023 was ¥0.71, a 1.43% increase from ¥0.70 in 2022[27]. - The company maintained a weighted average return on equity of 14.15% for 2023, down from 15.19% in 2022[27]. - Total assets increased by 4.28% to CNY 878.20 billion from CNY 842.18 billion in 2022[29]. - Total liabilities decreased by 2.09% to CNY 127.60 billion from CNY 130.32 billion in 2022[29]. - Operating cash flow increased by 7.56% to CNY 115.77 million from CNY 107.63 million in 2022[29]. - The company reported a revenue of CNY 408.05 million for 2023, unchanged from the preliminary report[31]. - The company achieved operating revenue of ¥408,049,692.89, a decrease of 7.71% compared to the same period last year[42]. - Net profit attributable to shareholders increased by 0.25% to ¥102,324,161.07, while net profit excluding non-recurring gains and losses grew by 12.09% to ¥88,279,575.36[42]. - The company’s total revenue for 2023 was approximately CNY 408 million, a decrease of 7.71% compared to CNY 442 million in 2022[56]. - The gross profit margin improved to 80.94% in 2023 from 79.96% in 2022[56]. - The net profit for 2023 was CNY 102.24 million, reflecting a slight increase of 0.63% from CNY 101.60 million in 2022[56]. Market Strategy and Development - The company plans to focus on expanding its market presence and enhancing its product development capabilities in the upcoming year[10]. - The company is actively pursuing new product development and technological advancements to strengthen its competitive position in the pharmaceutical industry[10]. - The company is actively expanding its OTC channel and enhancing its online sales system to build an efficient national marketing network[43]. - The company is committed to expanding its product pipeline and improving its pain relief product line through ongoing R&D efforts[43]. - The company plans to enhance its product pipeline and accelerate the launch of new products to maintain steady growth[51]. - The company aims to build a high-quality traditional Chinese medicine service system by 2025, enhancing its capabilities in disease prevention and treatment[50]. - The company is strategically positioning itself in the healthcare sector through investments in mental health and wellness-related businesses[79]. - The company plans to focus on product innovation and market expansion, with a strategic emphasis on digital marketing and e-commerce to drive sales growth[110]. - The company is committed to improving production management capabilities through smart upgrades and lean production practices, aiming to enhance quality and reduce costs[110]. - The company will expand its traditional Chinese medicine supply chain by increasing the scale and quality of herbal medicine cultivation[110]. Research and Development - The company holds 26 invention patents and 99 drug production approvals, focusing on CNS and digestive system drugs[38]. - The company has initiated 3 new R&D projects and holds a total of 84 patent certificates, including 26 invention patents[43]. - The company has five main R&D projects, including original Chinese medicine varieties, classic prescriptions, chemical generics, consistency evaluation of major varieties, and secondary development of exclusive traditional Chinese medicine products[199]. - The R&D team consists of over 50 personnel, including 1 PhD and 5 Master's degree holders, with 44.90% holding professional technical titles[199]. - The company employs a project-based collaborative R&D model, partnering with domestic universities and research institutions to enhance its research capabilities[199]. - The company has initiated three new drug R&D projects at the end of the reporting period, laying the groundwork for its development during the 15th Five-Year Plan[200]. - The company has developed a patented production process for its products, improving stability and reducing production costs[196]. - The company emphasizes the importance of intellectual property protection, focusing on the creation, registration, and safeguarding of patents, trademarks, and trade secrets[196]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures, including wastewater treatment and air quality management, achieving compliance with national standards[102]. - The company has established an emergency response mechanism for environmental pollution incidents, ensuring timely reporting and control of potential hazards[103]. - The company has received recognition for its employee welfare initiatives, including the "Model Workers' Home" award in Sichuan Province[97]. - The company maintains a focus on sustainable development, balancing economic benefits with social and environmental responsibilities[98]. - The company has successfully renewed its pollution discharge permits, demonstrating ongoing compliance with environmental regulations[100]. - The company actively responds to the national "Rural Revitalization" strategy by establishing a traditional Chinese medicine planting experimental base, contributing to local employment and income increase[96]. Corporate Governance and Management - The company has engaged Zhonghui Certified Public Accountants for its audit, receiving a standard unqualified opinion on its financial statements[10]. - The company has established a robust internal control system for revenue recognition to mitigate risks associated with improper revenue reporting[92]. - The company has engaged Zhonghui CPA as its external auditor for the 2023 annual audit, ensuring compliance with auditing standards[94]. - The company has implemented a stock incentive plan, granting 2.4 million restricted shares at a price of 3.21 yuan per share to 36 individuals[129]. - The company has repurchased 3 million shares using its own funds for the stock incentive plan, with a maximum repurchase price set at 9.00 yuan per share[130]. - The company has a total of 7 directors, 3 supervisors, and 4 senior management personnel[161]. - The company’s management remuneration is determined based on operational scale and industry salary levels[165]. - The company has focused on talent acquisition through various recruitment channels, including university graduates and social recruitment[171]. - The company conducted diverse training activities to improve employee professional skills, laying a solid foundation for future development[171]. Compliance and Risk Management - The company emphasizes compliance and risk management, aiming to establish a long-term risk prevention mechanism to protect investor interests[111]. - The company has implemented measures to control the quality of traditional Chinese medicinal materials from the source, including the establishment of a planting base[114]. - The company has not experienced any significant changes in major risks during the reporting period[115]. - The company has not faced any major litigation or arbitration matters during the reporting period[119]. Shareholder and Investor Relations - The company emphasizes investor relations management through various communication channels, ensuring transparency and engagement with small and medium investors[98]. - The company’s profit distribution proposal requires approval from the board and shareholders, ensuring transparency and consideration of minority shareholders' opinions[151]. - The company has maintained strict compliance with its fundraising management regulations, ensuring no misuse of funds by major shareholders or actual controllers[146]. - The company has not made any adjustments to its profit distribution policy during the reporting period[152]. Product Development and Sales - The company has launched a new product, Pregabalin Oral Solution, and is actively expanding its marketing network nationwide[66]. - The revenue from the main product, Sodium Cytidine, decreased by 11.71% year-on-year, particularly in the South and Central regions, where the decline reached 30%[66]. - The company reported a decrease in gross profit margin in the South region by 3.85 percentage points, while the Northwest region saw an increase of 6.10 percentage points[65]. - The company is focusing on expanding its OTC channel and enhancing its online sales system to improve market reach[190]. - The sales model primarily involves academic promotion and distribution through third-party agencies, ensuring compliance with industry regulations[191]. - The company has seen a 27.70% increase in revenue from other products, indicating successful diversification of its product offerings[190].

中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 四川梓樟宫药业股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 目 录 | 页 次 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-2 | | 二、四川梓ٽ官药业股份有限公司关于 2023年度募集资金 | | | | | 年度募集资金存放与 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2024-034 四川梓橦宫药业股份有限公司 2023 年度内部控制自我评价报告 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相 关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的 固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导 致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评价 结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日， 不存在财务报告内部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体 系和相关规定的要求在所有重大方面保持了有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基准日， 公司未发现非财务报告内部控制重大缺陷。 自内部控制评价报告基准日至内部控制评价报告发出日之间未发生影响内部控 制有效性评价结论的因素。 三、内部控制评价工作情况 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重 ...

公司本次以自有闲置资金购买理财产品的金额为人民币 2,000.00 万元， 截止目前，公司使用自有闲置资金购买理财产品的未到期余额为 21,894.00 万 元，占公司 2022 年度经审计净资产的 30.93%，达到上述披露标准，现予以披 露。 证券代码：832566 证券简称：梓橦宫 公告编号：2024-023 四川梓橦宫药业股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2023 年 9 月 28 日 召开第三届董事会第二十三次会议及 2023 年 10 月 20 日召开 2023 年第五次临 时股东大会，审议通过了《关于使用自有闲置资金购买理财产品的议案》。为 提高公司资金的使用效率，增加投资收益，在不影响公司主营业务的正常发展， 并确保公司正常经营需求的前提下，公司拟使用不超过人民币 35,000.00 万元 （含 35,000.00 ...